凯赛生物
(688065)
| 流通市值：280.66亿 | | | 总市值：347.01亿 |
| 流通股本：5.83亿 | | | 总股本：7.21亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 874,529,796.39 | 3,295,051,930.28 | 2,545,040,722.5 | 1,670,767,942.21 |
| 营业收入 | 874,529,796.39 | 3,295,051,930.28 | 2,545,040,722.5 | 1,670,767,942.21 |
| 二、营业总成本 | 715,775,081.82 | 2,575,128,035.09 | 1,946,642,190.87 | 1,283,596,878.98 |
| 营业成本 | 559,349,019.11 | 2,167,646,190.24 | 1,660,528,993.42 | 1,105,270,854.11 |
| 税金及附加 | 8,747,718.02 | 33,459,110.05 | 26,910,896.27 | 18,658,927.33 |
| 销售费用 | 14,858,727.05 | 60,062,652.36 | 44,514,491.83 | 29,289,681.12 |
| 管理费用 | 49,445,931.49 | 174,935,755.6 | 135,108,618.75 | 90,894,858.67 |
| 研发费用 | 56,867,479.51 | 237,891,987.96 | 178,566,777.26 | 123,198,537.35 |
| 财务费用 | 26,506,206.64 | -98,867,661.12 | -98,987,586.66 | -83,715,979.6 |
| 其中:利息费用 | 1,541,390.4 | 8,790,803.27 | 8,694,865.96 | 7,746,055.43 |
| 其中:利息收入 | 35,119,603.53 | 184,200,749.03 | 142,367,522.4 | 98,008,050.86 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | 5,657,569.11 | 2,172,228.69 |
| 加:投资收益 | -3,760,331.64 | 1,401,691.68 | -4,222,426.2 | -5,951,887.58 |
| 资产处置收益 | -5,422.84 | 6,708,160.46 | 6,717,488.5 | 5,194,901.42 |
| 资产减值损失(新) | 9,301,737.32 | -135,700,535.02 | -114,070,263.31 | -57,703,425.03 |
| 信用减值损失(新) | -2,178,134.41 | -11,728,738.54 | -15,653,816.42 | -6,894,765.82 |
| 其他收益 | 30,330,082.42 | 53,148,654.76 | 30,116,825.37 | 21,776,292.03 |
| 四、营业利润 | 192,442,645.42 | 633,753,128.53 | 506,943,908.68 | 345,764,406.94 |
| 加:营业外收入 | 125,935.07 | 726,675.26 | 590,321.17 | 449,569.69 |
| 减:营业外支出 | 510,050.9 | 4,314,974.85 | 4,114,750.58 | 4,101,537.05 |
| 五、利润总额 | 192,058,529.59 | 630,164,828.94 | 503,419,479.27 | 342,112,439.58 |
| 减:所得税费用 | 27,684,804.25 | 100,662,520.83 | 80,514,760.05 | 57,920,668.2 |
| 六、净利润 | 164,373,725.34 | 529,502,308.11 | 422,904,719.22 | 284,191,771.38 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 164,373,725.34 | 529,502,308.11 | 422,904,719.22 | 284,191,771.38 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 165,716,872.97 | 560,720,036.93 | 450,673,830.55 | 308,667,050.28 |
| 少数股东损益 | -1,343,147.63 | -31,217,728.82 | -27,769,111.33 | -24,475,278.9 |
| 扣除非经常损益后的净利润 | 147,633,535.85 | 520,694,503.24 | 428,560,042.97 | 296,452,653.46 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.23 | 0.82 | 0.67 | 0.47 |
| (二)稀释每股收益 | 0.23 | 0.82 | 0.67 | 0.47 |
| 八、其他综合收益 | 159,103.82 | 4,771,479.52 | 4,490,569.41 | 4,035,669.85 |
| 归属于母公司股东的其他综合收益 | 159,103.82 | 4,771,479.52 | 4,490,569.41 | 4,035,669.85 |
| 九、综合收益总额 | 164,532,829.16 | 534,273,787.63 | 427,395,288.63 | 288,227,441.23 |
| 归属于母公司股东的综合收益总额 | 165,875,976.79 | 565,491,516.45 | 455,164,399.96 | 312,702,720.13 |
| 归属于少数股东的综合收益总额 | -1,343,147.63 | -31,217,728.82 | -27,769,111.33 | -24,475,278.9 |
| 公告日期 | 2026-04-30 | 2026-04-24 | 2025-10-31 | 2025-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |